MT Newswires Live01-06
Shanghai Fosun Pharmaceutical (SHA:600196) said an investment fund it participates in has completed its private equity fund filing with the Asset Management Association of China.
The CR (Chengdu) Pharmaceutical Industry Equity Investment Fund was jointly established by Fosun Pharma's controlling subsidiary and 11 other investors in October 2025, according to a filing with the Shanghai bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
